Lessons learned from marketed and investigational prodrugs

被引：285

作者：

Ettmayer, P

Amidon, GL

Clement, B

Testa, B

机构：

[1] Novartis Inst BioMed Res, A-1235 Vienna, Austria

[2] Univ Michigan, Coll Pharm, Ann Arbor, MI 48109 USA

[3] Univ Kiel, Inst Pharmaceut, D-24118 Kiel, Germany

[4] CHU Vaudois, Dept Pharm, CH-1011 Lausanne, Switzerland

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2004年 / 47卷 / 10期

关键词：

D O I：

10.1021/jm0303812

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

[No abstract available]

引用

页码：2393 / 2404

页数：12

共 86 条

[41]

Keller TH, 2001, PROG RESPIR RES, V31, P237

[42]

KRAMER W, 1995, HIGH TECH DAS NEUE G, P61

[43] CLINICAL PHARMACOKINETICS OF THE ANGIOTENSIN CONVERTING ENZYME-INHIBITORS - A REVIEW [J].

KUBO, SH ;

CODY, RJ .

CLINICAL PHARMACOKINETICS, 1985, 10 (05) :377-391

[44]

LAMPIDIS TJ, 1989, ANTI-CANCER DRUG, V191, P29

[45] Influence of ferrous sulfate on the solubility, partition coefficient, and stability of mycophenolic acid and the ester mycophenolate mofetil [J].

Lidgate, D ;

Brandl, M ;

Holper, M ;

Abubakari, A ;

Wu, XY .

DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2002, 28 (10) :1275-1283

[46] THE MECHANISM OF ACTION OF THE GASTRIC-ACID SECRETION INHIBITOR OMEPRAZOLE [J].

LINDBERG, P ;

NORDBERG, P ;

ALMINGER, T ;

BRANDSTROM, A ;

WALLMARK, B .

JOURNAL OF MEDICINAL CHEMISTRY, 1986, 29 (08) :1327-1329

[47]

Luer MS, 1998, NEUROL RES, V20, P178

[48]

Maeda H, 2002, BIOMEDICAL ASPECTS OF DRUG TARGETING, P211

[49]

Major PP, 2000, CANCER, V88, P6, DOI 10.1002/(SICI)1097-0142(20000101)88:1<6::AID-CNCR3>3.0.CO

[50]

2-D

← 1 2 3 4 5 6 7 8 9 →